First‐trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free β‐hCG and PAPP‐A: a 5‐year prospective study
- 26 April 2012
- journal article
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 39 (5) , 528-534
- https://doi.org/10.1002/uog.10051
Abstract
Objective To investigate the performance of first‐trimester screening for chromosomal abnormalities by integrated application of nuchal translucency thickness (NT), nasal bone (NB), tricuspid regurgitation (TR) and ductus venosus (DV) flow combined with maternal serum free β‐human chorionic gonadotropin (fβ‐hCG) and pregnancy‐associated plasma protein‐A (PAPP‐A) at a one‐stop clinic for assessment of risk (OSCAR). Methods In total, 13 706 fetuses in 13 437 pregnancies were screened for chromosomal abnormalities during a period of 5 years. Maternal serum biochemical markers and maternal age were evaluated in combination with NT, NT + NB, NT + NB + TR, and NT + NB + TR + DV flow data in 8581, 242, 236 and 4647 fetuses, respectively. Results In total, 51 chromosomal abnormalities were identified in the study population, including 33 cases of trisomy 21, eight of trisomy 18, six of sex chromosome abnormality, one of triploidy and three of other unbalanced abnormalities. The detection rate and false‐positive rate (FPR) for trisomy 21 were 93.8% and 4.84%, respectively, using biochemical markers and NT, and 100% and 3.4%, respectively, using biochemical markers, NT, NB, TR and DV flow. Conclusion While risk assessment using combined biochemical markers and NT measurement has an acceptable screening performance, it can be improved by the integrated evaluation of secondary ultrasound markers of NB, TR and DV flow. This enhanced approach would decrease the FPR from 4.8 % to 3.4 %, leading to a lower number of unnecessary invasive diagnostic tests and subsequent complications, while maintaining the maximum level of detection rate. Pre‐ and post‐test genetic counseling is of paramount importance in either approach. Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd.Keywords
This publication has 30 references indexed in Scilit:
- Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13 weeks of gestationUltrasound in Obstetrics & Gynecology, 2009
- Fetal tricuspid regurgitation at the 11 + 0 to 13 + 6‐week scan: association with chromosomal defects and reproducibility of the methodUltrasound in Obstetrics & Gynecology, 2006
- Likelihood ratio for trisomy 21 in fetuses with tricuspid regurgitation at the 11 to 13 + 6-week scanUltrasound in Obstetrics & Gynecology, 2005
- Absent nasal bone at 11–14 weeks of gestation and chromosomal defectsUltrasound in Obstetrics & Gynecology, 2003
- Measurement of nasal bone length at 11–14 weeks of pregnancy and its potential role in Down syndrome risk assessmentUltrasound in Obstetrics & Gynecology, 2003
- Association between first trimester absence of fetal nasal bone on ultrasound and Down syndromePrenatal Diagnosis, 2002
- The first trimester ‘combined test’ for the detection of Down syndrome pregnancies in 4939 unselected pregnanciesPrenatal Diagnosis, 2002
- Absence of nasal bone in fetuses with trisomy 21 at 11–14 weeks of gestation: an observational studyThe Lancet, 2001
- Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern FinlandEuropean Journal of Human Genetics, 2001
- Ductus venosus studies in fetuses at high risk for chromosomal or heart abnormalities: relationship with nuchal translucency measurement and fetal outcomeUltrasound in Obstetrics & Gynecology, 2001